Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature

D. Pastorelli, G. Cartei, F. Zustovich, F. Marchese, G. Artioli, S. Zovato, S. Binato, R. Ceravolo, S. Cingarlini, F. Salmaso, M. Mattiazzi, C. Sanavio, F. Farinati, G. Zanus, U. Cillo

Research output: Contribution to journalArticle

Abstract

Background: Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option. Pa tients and methods: Clinical trials for biliary and hepatic carcinoma have been reviewed. Results: We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m2 d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).

Original languageEnglish
JournalAnnals of Oncology
Volume17
Issue numberSUPPL. 5
DOIs
Publication statusPublished - May 2006

Keywords

  • Biliary tract cancers
  • Chemotherapy
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature'. Together they form a unique fingerprint.

  • Cite this

    Pastorelli, D., Cartei, G., Zustovich, F., Marchese, F., Artioli, G., Zovato, S., Binato, S., Ceravolo, R., Cingarlini, S., Salmaso, F., Mattiazzi, M., Sanavio, C., Farinati, F., Zanus, G., & Cillo, U. (2006). Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature. Annals of Oncology, 17(SUPPL. 5). https://doi.org/10.1093/annonc/mdj972